Joint problems in breast cancer patients receiving adjuvant aromatase inhibitor
Kuria, I.M.; Petekkaya, I.; Hasanov, E.; Babacan, T.; Dizdar, O.; Altundag, K.
Journal of BUON Official Journal of the Balkan Union of Oncology 17(4): 798-799
2012
ISSN/ISBN: 1107-0625 PMID: 23335547 Document Number: 657584
Document emailed within 1 workday
Related Documents
Kao, Y.C.; Okubo, T.; Sun, X.Z.; Chen, S. 1999: Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women Anticancer Research 19(3a): 2049-2056De Jong, P.C.; van de Ven, J.; Nortier, H.W.; Maitimu-Smeele, I.; Donker, T.H.; Thijssen, J.H.; Slee, P.H.; Blankenstein, R.A. 1997: Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole Cancer Research 57(11): 2109-2111
Kubota, O.; Onuki, Y.; Uchiyama, T.; Oishi, K.; Takeda, M. 2012: Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(5): 753-757
Irawan, C.; Abdulmuthalib 2005: The role of aromatase inhibitor (AI) in the treatment of breast cancer Acta Medica Indonesiana 37(1): 43-48
Koyama, H.; Iesato, A.; Fukushima, Y.; Okada, T.; Watanabe, T.; Harada, M.; Ito, T.; Maeno, K.; Mochizuki, Y.; Ito, K.; Amano, J. 2011: A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1123-1126
Semiglazov, V.F.; Maximov, S.Y.; Bulgatova, Y., A.; Meshkova, I.Y.; Chepik, O.F.; Berstein, L.M. 2003: Risk of hyperplasia and endometrial carcinoma in breast cancer patients receiving adjuvant tamoxifen Voprosy Onkologii (Stsburg). 49(2): 198-204
Tsukagoshi, S. 2006: Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(6): 859-863
Stein, R.C.; Dowsett, M.; Davenport, J.; Hedley, A.; Ford, H.T.; Gazet, J.C.; Coombes, R.C. 1990: Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A Cancer Research 50(5): 1381-1384
Takeda, Y.; Tanaka, N.; Konishi, J. 2012: Combination of trastuzumab, aromatase inhibitor and anti-cancer drugs obtained a good prognosis for an inoperable stage IIi B breast cancer patient with giant skin ulceration Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(4): 629-632
Baba, S.; Oji, Y.; Teramoto, M.; Kawabata, K.; Saito, A. 2009: A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(11): 1905-1906
Vincent, F.; Labourey, J.L.; Leobon, S.; Antonini, M.T.; Lavau-Denes, S.; Tubiana-Mathieu, N. 2013: Effects of a home-based walking training program on cardiorespiratory fitness in breast cancer patients receiving adjuvant chemotherapy: a pilot study European journal of physical and rehabilitation medicine 49(3): 319-329
Barni, S.; Lissoni, P.; Meregalli, S.; Ardizzoia, A.; Mengo, S.; Musco, F.; Merlini, D.; Tancini, G. 1998: Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer Tumori 84(1): 45-47
Mathoulin-Portier, M.P.; Meynard, P.; Charton-Bain, M.C.; Escoute, M.; Bardou, V.J.; Puig, B.; Viens, P.; Cowen, D.; Houvenaeghel, G.; Hassoun, J.; Jacquemier, J. 1999: Peritumoral vascular invasion in women with node-negative breast cancer, receiving no adjuvant therapy Anticancer Research 19(1b): 843-847
Crivellari, D. 2002: Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group Tumori 88(1 Suppl. 1): S81-S82
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Abe, R.; Tsuchiya, A.; Koie, H.; Ono, K.; Abo, S.; Saito, K.; Tsukamoto, M.; Sato, T.; Mori, S.; Motoki, R. 1988: Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(9): 2707-2712
Harbeck, N.; Kates, R.E.; Look, M.P.; Meijer-Van Gelder, M.E.; Klijn, J.G.M.; Krüger, A.; Kiechle, M.; Jänicke, F.; Schmitt, M.; Foekens, J.A. 2002: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Research 62(16): 4617-4622
Ohtake, T.; Yasuda, M.; Watanabe, K.; Ito, T.; Ito, J.; Miyamoto, K.; Yoshida, S.; Abe, N.; Ishigame, T.; Ishii, M.; Kimijima, I.; Takenoshita, S. 2009: Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(9): 1459-1463
Altundag, K. 2018: Concurrent administration of aromatase inhibitors with chemotherapy might show better outcome in high risk hormone-receptor positive early-stage breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1559-1560
Semiglazov, V.F.; Bavli, I.L.; Moiseenko, V.M. 1986: Adjuvant therapy of breast cancer patients Voprosy Onkologii 32(11): 59-63